[ET Net News Agency, 20 June 2018] Luye Pharma (02186) said the Group's product
candidate, rotigotine extended release microspheres for injection (LY03003), commenced
phase III clinical trial in the People's Republic of China.
LY03003 is one of the Group's key central nervous system product candidates developed on
a long acting and extended-release formulation platform. The drug is being concurrently
developed in the markets of China, the United States, Europe and Japan, and has completed
Phase I clinical trials and is exempted from Phase II clinical trials in both China and
the United States. The Group plans to register and launch LY03003 in China, the United
States, Japan, Europe and other countries.
LY03003 delivers medication by weekly intramuscular injections. It is the first product
worldwide to produce long-term Continuous Dopamine Stimulation. The stable release of the
drug in the human body can reduce the "on-off" phenomenon common in drug treatments for
patients with Parkinson's disease, and significantly improves motor complications common
among patients with late-stage Parkinson's disease. (HL)